Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Intuitive Surgical stock edges higher on EU da Vinci SP approval and solid Q2 growth

AI-generated analysis

📈 Intuitive Surgical stock closed at USD 383.54 on September 17, 2026, gaining 0.33% as investors reacted to new EU approval for the da Vinci SP system.

✅ The European CE mark now covers transvaginal gynecologic procedures for the da Vinci SP, expanding the platform's approved indications in the region.

📊 Q2 2026 fundamentals showed year-on-year growth in revenue and da Vinci procedure volume, underscoring continued business expansion.

💰 Recurring revenue from instruments and accessories grew in Q2 2026, strengthening the company's razor-and-blades ecosystem model.

🎯 Analysts maintain a Moderate Buy rating with an average price target of USD 508.68, suggesting roughly 32.6% upside potential.

📉 Shares have declined 32.3% year-to-date in 2026 from a high of USD 566.36, creating a valuation contrast with operational growth.

👔 Vice President Fredrik Widman sold 1,089 shares under a Rule 10b5-1 plan for approximately USD 407,765 on September 17.

🏦 Institutional investors hold roughly 83.6% of Intuitive Surgical's outstanding shares, indicating strong professional ownership.

🔬 The company continues to expand its installed base of da Vinci systems while maintaining momentum in robotic procedures.

Bullish Signals
  • Intuitive Surgical received CE mark approval in Europe for the da Vinci SP system to perform transvaginal gynecologic procedures, expanding its market presence.
  • Q2 2026 revenue and da Vinci procedure volume both increased year-on-year, demonstrating sustained business momentum despite stock price corrections.
  • The company reported continued growth in installed da Vinci systems and recurring revenue from instruments and accessories in Q2 2026.
  • Analyst consensus rates the stock as a Moderate Buy with an average price target of USD 508.68, implying approximately 32.6% upside from current levels.
  • Institutional investors maintain a dominant 83.6% ownership stake in Intuitive Surgical shares, reflecting strong professional confidence.
Risk Factors
  • Intuitive Surgical shares have fallen by 32.3% year-to-date in 2026 from a starting level of USD 566.36, trading below typical analyst valuation benchmarks.
  • Vice President Fredrik Widman sold 1,089 shares worth approximately USD 407,765 under a Rule 10b5-1 plan on September 17, 2026.
Full Analysis
Intuitive Surgical (ISRG) shares edged higher on September 17, 2026, closing at USD 383.54 on the Nasdaq following a significant regulatory milestone and strong quarterly performance. The company received CE mark approval in Europe for its da Vinci SP single-port robotic system to perform transvaginal gynecologic procedures, expanding its approved indications and deepening its presence in minimally invasive women's health markets. Fundamental growth remains robust despite a broader stock correction of 32.3% year-to-date in 2026. The second quarter of 2026 delivered year-on-year increases in both revenue and da Vinci procedure volume, validating the company's expansion strategy. Additionally, Intuitive Surgical highlighted continued growth in installed systems and recurring revenue from instruments and accessories, reinforcing the durability of its razor-and-blades business model. Analyst sentiment remains positive with a consensus rating of Moderate Buy and an average price target of USD 508.68, implying approximately 32.6% upside from current levels. While Vice President Fredrik Widman executed a planned Rule 10b5-1 sale of shares worth roughly USD 407,765, institutional investors maintain a dominant 83.6% ownership stake, signaling strong professional confidence in the company's long-term trajectory and valuation entry point.